News for Nutriband Inc. (NTRB)

PALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's esti

Nutriband (NTRB) completes the commercial manufacturing process scale-up of its Aversaâ„¢ Fentanyl patch. Aversaâ„¢ Fentanyl aims to be the first abuse-

Nutriband (NTRB) has successfully scaled up the commercial manufacturing process for its flagship product, Aversa Fentanyl, in collaboration with Kindeva. This

**media[658218]**

Patent issuance expands United States patent coverage for AVERSAâ„¢ transdermal abuse deterrent technology AVERSAâ„¢ transdermal abuse deterrent technology is

Nutriband Inc. (NTRB) has been granted U.S. patent number 12,318,492 for its AVERSA abuse deterrent transdermal technology. This patent significantly st

Nutriband (NTRB) has successfully acquired a patent from the United States Patent and Trademark Office, identified as patent number 12,318,492, on June 3, 2025.

ORLANDO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NTRB) (NTRBW) today announced that CEO, Gareth Sheridan will present at Noble Capital Markets

Nutriband (NTRB) is enhancing its production capabilities through its subsidiary, Pocono Pharma, to increase its share in the kinesiology tape market. The compa

ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NTRB) (NTRBW) reported its financial results for the first quarter ended April 30, 2025. N

Nutriband (NTRB) delivered earnings and revenue surprises of 7.69% and 6.06%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?

AUSTIN, Texas, May 27, 2025 (GLOBE NEWSWIRE) -- via IBN ”“ IBN, a multifaceted communications organization engaged in connecting public companies to the inve

Nutriband (NTRB) recently shared a letter from CEO Gareth Sheridan, outlining significant achievements in 2024 and a positive outlook for 2025. The company emph

ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NTRB)(NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders

California-based Regulus Therapeutics Inc. (RGLS), a clinical-stage biopharmaceutical company is up over 132 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

AVERSA Fentanyl projected to achieve $80M-$200M in peak annual sales. Nutriband (NTRB) raised $8.4M in April 2024 through a private placement. Company hold

Nutriband Inc. (NTRB), a company specializing in innovative transdermal technology, has secured a crucial patent for its AVERSA abuse deterrent system in Macao.

Nutriband Inc. (NTRB) has secured a patent in Macao for its AVERSA abuse deterrent transdermal technology. The AVERSA technology now holds patents in 46

**media[592468]**